Today's Trend
Gentex Corporation (NASDAQ: GNTX) is under pressure after a mix of analyst estimate changes and insider selling, even as some longer-term earnings forecasts were nudged higher. The stock has been drifting lower, with investors weighing a modestly negative near-term earnings revision against a still-solid underlying outlook.
- Zacks Research raised its FY2026 EPS estimate for Gentex to $1.91 from $1.89 and also increased its Q2 2027 and Q3 2027 forecasts, signaling improving expectations for medium-term earnings growth.
- JPMorgan recently lifted its price target on Gentex to $28 from $27, suggesting Wall Street sees somewhat better valuation support despite keeping a neutral rating.
- Gentex’s last quarterly report beat expectations on both earnings and revenue, which continues to support the investment case. Gentex stock page
- Director Brian Walker sold 5,939 shares for about $136,478 at $22.98 per share, a transaction that may be viewed cautiously by investors but is not, by itself, a major fundamental change. Gentex director sale article
- Gentex remains a profitable auto supplier with a relatively low valuation and a 2.1% dividend yield, which may help cushion downside. Gentex stock page
- Zacks Research trimmed Q4 2026 EPS to $0.47 from $0.48 and cut Q1 2027 EPS to $0.51 from $0.54, reinforcing some near-term caution around the next few quarters.
- The firm also lowered its Q4 2027 EPS estimate and reduced FY2027 EPS to $2.13 from $2.17, which may weigh on sentiment for Gentex’s longer-dated growth outlook.
Overall, Gentex (NASDAQ: GNTX) is moving lower as investors react to mixed analyst revisions and insider selling, despite recent earnings strength and some improved medium-term forecasts.